

Remarks/Arguments

The patent office Notice to Comply mailed April 1, 2008 points out that the amino acid sequence provided on page 8 and claim 4 does not provide a sequence identifier. In reviewing the application, "LPXTGVI" was also identified as lacking a sequence identifier.

The present amendment to the specification and claims provides sequence identifiers for the generic amino acid sequence provided on page 8 (SEQ ID NO: 58); amends claim 4 to provide the same generic amino acid sequence as on page 8 (SEQ ID NO: 58); and amends the specification to provide a sequence identifier for "LPXTGVI" (SEQ ID NO: 57). The variables X¹ to X⁷⁹ for the generic amino acid sequence listing (SEQ ID NO: 59) was obtained using the variables provided on page 8, line 16 to page 10, line 25.

The contents of the enclosed paper and computer readable form of the sequence listing are the same. The sequence listing was amended to provide an updated general information sequence and, as noted above, to provide SEQ ID NOs: 57 and 58. Thus, no new matter was introduced into the Sequence Listing.

Please charge deposit account 13-2755 for fees due in connection with this response. If any time extensions are needed for the timely filing of the present response, applicants petition for such extensions and authorize the charging of deposit account 13-2755 for the appropriate fees.

Respectfully submitted,

By 
Sheldon O. Heber
Reg. No. 38,179
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-1958